Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/22/2003WO2002056912A3 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
05/22/2003WO2002053740A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/22/2003WO2002050283A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
05/22/2003WO2002045749A8 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
05/22/2003WO2002044183A3 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
05/22/2003WO2002044168A3 Indole-type inhibitors of p38 kinase
05/22/2003WO2002041879A3 Antidiabetic compositions containing a biguanide and a sulfonamide
05/22/2003WO2002024187A3 Treatment of diseases with adamantane derivatives
05/22/2003US20030097667 For therapy of Alzheimers disease, diagnosis
05/22/2003US20030097665 To produce phosphorylated lysosomal proteins which are incorporated into pharmaceutical formulations for use in enzyme replacement therapy
05/22/2003US20030097220 System and methods for optimized drug delivery and progression of diseased and normal cells
05/22/2003US20030097023 For prophylaxis and therapy of immunological diseases, asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia
05/22/2003US20030097004 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists
05/22/2003US20030096998 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096866 Methods for activating lipid catabolism and improving lipid metabolism in small intestinal epithelium
05/22/2003US20030096862 Stable NO-delivering compounds
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096857 Novel antidiabetic agents
05/22/2003US20030096856 Compounds such as N-((dimethylamino)acetyl)-1-methyl-N-(3, 4,5-trimethoxyphenyl)-1H-indole-5-sulfonamide for therapy of cancer
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096842 Inhibitors of farnesyl protein transferase
05/22/2003US20030096841 For treatment of cancers, heart disease, such as congestive heart failure, osteoporosis, genetic, inflammatory, allergic, and autoimmune diseases
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096838 Novel triazolo-pyridines anti-inflammatory compounds
05/22/2003US20030096834 Pharmaceutical compositions
05/22/2003US20030096833 Use in inhibiting inflammation, cell death and in treating shock and reperfusion injuries
05/22/2003US20030096830 Pyrrolo(3,2-d)pyrimidin-7-yl)-1,4-imino-D-ribitol derivatives; for suppression of T-cell function
05/22/2003US20030096829 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096826 Inhibitors of interleukin-1 beta converting enzyme and other cysteine proteases in the ICE family
05/22/2003US20030096824 Substituted phenylamidines medicaments containing said compounds and method for production thereof
05/22/2003US20030096823 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003US20030096820 Nitrogen containing heterobicycles as factor Xa inhibitors
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096802 Pentanoic acid derivatives
05/22/2003US20030096800 Estrogenic compounds as anti-mitotic agents
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096793 Inhibit protease enzymes; Benzyl 5-(benzoylamino)-4,4-dihydroxy-7- methyl-4-sila-octanamide, for example can be used to inhibit HIV protease in the treatment of AIDS
05/22/2003US20030096784 Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase)
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096774 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
05/22/2003US20030096769 Genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes
05/22/2003US20030096765 Aromatic esters; cytotoxic agents; antitumor agents
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096754 Vascular endothelial growth factor variants
05/22/2003US20030096752 Net charge of -3-3 at pH 7 and with the amino acids arginine15 or arginine15-alanine17 in the binding region; serine protease inhibitors
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096356 G protein-coupled receptor protein for use in the diagnosis and treatment of alzheimer's disease
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096287 Oligonucleotide for use as diagnostic tool in genetic engineering
05/22/2003US20030096286 Oligoribonucleotides and ribonucleases for cleaving RNA
05/22/2003US20030096247 Human cDNAs and proteins and uses thereof
05/22/2003US20030096030 Extracting materials from the shell of Xanthoceras sorbifolia Bunge and applying the extracted materials to making drugs and functional foods
05/22/2003US20030096027 Alpha acid, (e.g., humulone) or beta acid (e.g., lupulone)
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/22/2003US20030095960 Three human transferases, polynucleotides that identify and encode them, expression vectors, host cells, antibodies, agonists, and antagonists.
05/22/2003US20030095955 Provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
05/22/2003US20030095954 Growth factor gene fused with secretory signal sequence is introduced into fibroblasts ex-vivo using adenovirus vector; infecting cultured non-hematocytes with the vector; administering the cells
05/22/2003US20030095946 Il-18 as an osteoclastgenic inhibitor
05/22/2003CA2472019A1 Production of cell suspensions
05/22/2003CA2468497A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003CA2468171A1 Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
05/22/2003CA2467391A1 Oligopeptides and compositions containing them as cathepsin s inhibitors
05/22/2003CA2467347A1 Histamine receptor h3 polynucleotides
05/22/2003CA2467267A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003CA2467258A1 Agent for inducing embryonic stem cell to ectodermal cell, method for obtaining the same and use of the same.
05/22/2003CA2467239A1 Catheter injectable depot compositions and uses thereof
05/22/2003CA2467229A1 Dexrazoxane for treating antitumor-induced cardiotoxicity
05/22/2003CA2467081A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003CA2467068A1 C-5 modified indazolylpyrrolotriazines
05/22/2003CA2466998A1 Biocompatible polymer blends and uses thereof
05/22/2003CA2466971A1 Benzimidazol- or indol-aminoacetonitrile derivatives for parasite control
05/22/2003CA2466962A1 Aryl aniline beta-2 adrenergic receptor agonists
05/22/2003CA2466659A1 Anticancer agents
05/22/2003CA2466592A1 Modified anti-tnf alpha antibody
05/22/2003CA2466521A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
05/22/2003CA2466519A1 Method for treating autoimmune diseases
05/22/2003CA2466504A1 Oral dosage form of a sulfonamide prodrug
05/22/2003CA2466415A1 Pgc-1.beta., a novel pgc-1 homologue and uses therefor
05/22/2003CA2466346A1 Single nucleotide polymorphisms in gh-1
05/22/2003CA2466344A1 Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
05/22/2003CA2466264A1 Three-dimensional structure of prostaglandin d synthase and utilization thereof
05/22/2003CA2466118A1 Modulation of lir function to treat rheumatoid arthritis
05/22/2003CA2466115A1 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003CA2466055A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003CA2465893A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003CA2465861A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003CA2464861A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2464419A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003CA2464347A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2464069A1 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof
05/22/2003CA2463639A1 Growth hormone variations in humans and their uses
1 ... 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 ... 1564